Streetbeat News

Analyst Ratings

NEM

Financial giants have shown a bullish interest in Newmont (NYSE:NEM) with significant options trading activity. Analysts have upgraded their ratings, and the stock is currently trading at $53.28. The predicted price range for NEM is between $32.5 and $60.0.

Portfolio Pulse from Benzinga Insights

September 16, 2024 | 4:45 pm

FCX

Recent options activity for Freeport-McMoRan (NYSE:FCX) shows a bullish sentiment among major investors, with 63% of trades being bullish. The stock is currently trading at $43.32, with a predicted price range of $42.0 to $60.0. Analysts have given positive ratings, with price targets between $52 and $55.

Portfolio Pulse from Benzinga Insights

September 16, 2024 | 4:45 pm

INCY

Guggenheim analyst Michael Schmidt has maintained a Buy rating on Incyte (NASDAQ:INCY) and raised the price target from $86 to $92.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 4:45 pm

OVV

Morgan Stanley analyst Devin McDermott has maintained an Equal-Weight rating on Ovintiv (NYSE:OVV) but has lowered the price target from $53 to $51.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 4:44 pm

NUVL

Guggenheim analyst Kelsey Goodwin has maintained a Buy rating on Nuvalent (NASDAQ:NUVL) and increased the price target from $99 to $105.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 4:43 pm

AR

Morgan Stanley has maintained its Overweight rating on Antero Resources but has slightly lowered the price target from $39 to $38.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 4:40 pm

U

Wedbush analyst Michael Pachter maintains an Outperform rating on Unity Software and raises the price target from $21 to $27.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 4:38 pm

RRC

Morgan Stanley analyst Devin McDermott maintains an Underweight rating on Range Resources (NYSE:RRC) and lowers the price target from $33 to $31.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 4:38 pm

CRVS

Ladenburg Thalmann has maintained a Buy rating on Corvus Pharma and raised the price target from $12 to $21, indicating a positive outlook for the company's stock.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 4:37 pm

NUVL

Wedbush analyst David Nierengarten has maintained an Outperform rating on Nuvalent (NASDAQ:NUVL) and raised the price target from $99 to $115.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 4:36 pm